Back to top
more

Vertex Pharmaceuticals (VRTX)

(Delayed Data from NSDQ)

$483.00 USD

483.00
2,259,829

-15.73 (-3.15%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Vertex Pharmaceuticals (VRTX) Q4 Earnings and Revenues Top Estimates

Vertex (VRTX) delivered earnings and revenue surprises of 40.50% and 41.36%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Big Drug/Biotech Stock Earnings on Jan 30: BIIB, ALXN & More

Let us take a look at five big drug/biotech companies due to release their quarterly results on Jan 30.

Why Vertex (VRTX) Might Surprise This Earnings Season

Vertex (VRTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings.

Can CF Drugs Drive Growth for Vertex (VRTX) in Q4 Earnings?

On Vertex's (VRTX) fourth-quarter earnings call, investor focus will be on the sales uptake of its CF drugs and the unveiling plans for the newly-approved Trikafta triple combination regimen.

Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $233.91, moving -0.3% from the previous trading session.

Vertex Pharmaceuticals (VRTX) Expected to Beat Earnings Estimates: Should You Buy?

Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Vertex (VRTX) is Poised to Beat Earnings Estimates Again

Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $226.49, moving -1.07% from the previous trading session.

Vertex Pharmaceuticals (VRTX) Stock Moves -0.11%: What You Should Know

Vertex Pharmaceuticals (VRTX) closed at $223.79 in the latest trading session, marking a -0.11% move from the prior day.

Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $218.95, moving -0.01% from the previous trading session.

The Zacks Analyst Blog Highlights: Medtronic, United Technologies, Union Pacific, Vertex Pharmaceuticals and NextEra Energy

The Zacks Analyst Blog Highlights: Medtronic, United Technologies, Union Pacific, Vertex Pharmaceuticals and NextEra Energy

Mark Vickery headshot

Top Research Reports for Medtronic, United Technologies & Union Pacific

Today's Research Daily features new research reports on 16 major stocks, including Medtronic (MDT), United Technologies (UTX) and Union Pacific (UNP).

Sweta Killa headshot

Biotech Leading in Q4: Best ETFs & Stocks

We highlight five biotech ETFs and stocks that are leading the market in Q4.

Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $219.98, moving -0.32% from the previous trading session.

Is Vertex Pharmaceuticals (VRTX) Stock Outpacing Its Medical Peers This Year?

Is (VRTX) Outperforming Other Medical Stocks This Year?

Tirthankar Chakraborty headshot

New Strong Buy Stocks for December 20th

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for today:

Benjamin Rains headshot

3 Tech Stocks for Growth Investors to Buy for 2020

Check out three tech stocks we found with our Zacks Stock Screener that growth investors might want to consider buying for 2020...

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

Sector ETF report for PBE

Ekta Bagri headshot

Biotech Stock Outlook: M&A Activity Retains Growth Streak

The biotech sector enjoys a good run in 2019 on the back of the M&A activities and positive pipeline updates underway. We expect this momentum to stay in 2020 as well.

Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $217.62, marking a -0.86% move from the previous day.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for December 16th

Here are 4 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday

Benjamin Rains headshot

Stocks Hit Records on China Trade Hope & Buy this Biotech Stock - Free Lunch

The latest U.S-China trade war news that includes a positive tweet from President Trump that helped lift stocks to new highs. A look at LULU's earnings. And why Vertex Pharmaceuticals (VRTX) is a Zacks Rank #1 (Strong Buy) stock right now...

Nitish Marwah headshot

New Strong Buy Stocks for December 12th

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday.

Vertex's Kalydeco Gets EU Approval to Treat CF in Infants

Vertex's (VRTX) Kalydeco gains EU nod for use in infants with cystic fibrosis aged from six to less than 12 months with at least one of specified nine mutations in the CFTR gene.

Looking for a Growth Stock? 3 Reasons Why Vertex (VRTX) is a Solid Choice

Vertex (VRTX) possesses solid growth attributes, which could help it handily outperform the market.